Ensayos clínicos

Inclusion Criteria:

1. Squamous cell carcinoma of the cervix (any grade) or histologically confirmed grade 1 or 2 adenocarcinoma of cervix
2. FIGO stage IA2 or IB1 disease
3. Tumor diameter ≤ 2 cm on physical exam & imaging studies (if performed)
4. No lymphovascular space invasion present on biopsy or previous cone
5. Less than 10mm of cervical stromal invasion
6. Cone margins and endocervical curettage (ECC) specimen negative for invasive cancer, cervical intraepithelial neoplasia (CIN) CIN II, CIN III or adenocarcinoma-in-situ (A negative margin is defined as no invasive cancer within 5.0mm of the margin and no AIS or CIN II or CIN III at the inked or cauterized margin; one repeat cone and ECC permitted)
7. Patients are eligible for the study when a cone and ECC are performed prior to pre-enrollment in the study, and pathologic eligibility criteria are met. The cone and ECC must be performed within 12 weeks prior to pre-enrollment in the study. If the cone and ECC performed prior to pre-enrollment do not meet the pathologic criteria, patients may be pre-enrolled and are allowed 1 repeat cone & ECC after pre-enrollment in order to meet pathologic eligibility criteria.
8. Patients must sign approved ICD
9. If patient is of childbearing potential, must have a negative blood or urine pregnancy test within 14 days of surgical treatment on study.
10. Patients who have had a simple hysterectomy (cut-through hysterectomy) prior to enrollment are eligible, provided the above pathology criteria are met. If lymphadenectomy was performed the lymph nodes must be negative. If lymphadenectomy was not performed, patients will undergo this procedure as part of the study.

Exclusion Criteria:

1. Clear cell, neuroendocrine, adenosquamous, serous carcinoma or other high-risk histologies
2. Grade 3 adenocarcinoma
3. FIGO stage IA1, IB2, II, III or IV disease
4. Tumors >2 cm in diameter on physical exam or imaging studies (if performed)
5. Presence of LVSI
6. Greater than or equal to 10mm of cervical stromal invasion
7. Cone margins or ECC specimen positive for invasive cancer, CIN II, CIN III or adenocarcinoma-in-situ (one repeat cone permitted)
8. Neoadjuvant radiation therapy or chemotherapy for cervical cancer
9. Patients unwilling or unable to provide informed consent for the study